IP Verse

Rapid Dissolution Formulation Of A Calcium Receptor-Active Compound

PatentPatent Analysis

EP3578175

AMGEN
Application Number
EP19164145A
Filing Date
Sep 10, 2004
Status
Granted And Under Opposition
Oct 28, 2022
Grant Date
Nov 30, 2022
External Links
Slate, Register, Google Patents
Similar Patents facing opposition
EP3570885B1
EP4209499B1
EP3819007B1

Biblio Summary

The patent EP3578175B1 was granted to Amgen on Nov 30, 2022 following the initial filing on Sep 10, 2004 under the application number EP19164145A . The current legal status of the patent is Granted And Under Opposition.

AI Generated Summary New

Patent Family

Patent Oppositions filed by Competitors

Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.

CompanyOpposition DateOpposition Status

Get instant alerts for new oppositions and patent status changes

BIOGARANAug 30, 2023ADMISSIBLE
GLENMARK PHARMACEUTICALS EUROPEAug 30, 2023ADMISSIBLE
TAD PHARMAAug 30, 2023WITHDRAWN
ARROW GENERIQUES PUREN PHARMAAug 29, 2023ADMISSIBLE
ELKINGTON AND FIFEAug 29, 2023ADMISSIBLE
SANDOZAug 29, 2023ADMISSIBLE
HAMM & WITTKOPPAug 24, 2023ADMISSIBLE

Dossier Documents of the Patent

The dossier documents provide a comprehensive record of the patent’s prosecution history, including filings, correspondence, and decisions made by patent offices. These documents are crucial for understanding the patent’s legal journey and any challenges it may have faced during examination. It also includes the oppositions documents filed against the patent.

  • Date

    Description

  • Get instant alerts for new documents